By Andrea Figueras

 

Roche said that it has received positive long-term follow-up data and significant overall survival benefit from the Katherine study, which examines people with early-stage breast cancer.

The study evaluated the efficacy and safety of Kadcyla versus Herceptin as an adjuvant therapy, the Swiss pharmaceutical company said on Friday, pointing out that data showed continued benefit for the first one as it reduced the risk of disease recurrence or death from any cause by 46% compared with Herceptin.

"Katherine results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date," Roche said.

At three years, 88.3% of people treated with Kadcyla didn't have their breast cancer return compared with 77% treated with Herceptin, an absolute improvement of 11.3%, the company said.

Kadcyla is approved in 113 countries and is the standard of care for people with HER2-positive early-stage breast cancer with residual invasive disease after a pre-surgery treatment, it said.

 

Write to Andrea Figueras at andrea.figueras@wsj.com

 

(END) Dow Jones Newswires

December 08, 2023 12:40 ET (17:40 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Roche (QX) 차트를 더 보려면 여기를 클릭.
Roche (QX) (USOTC:RHHBY)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Roche (QX) 차트를 더 보려면 여기를 클릭.